BioSpace News Archive

Publication to provide targeted news; career opportunities; and educational resources for thousands of water quality professionals

Technavio has announced the release of their research report on the global osteoporosis drugs market for the forecast period 2019-2023. This osteoporosis drugs market analysis report segments the market by product (antiresorptive drugs and anabolic drugs) and geography (Asia, Europe, North America, and ROW).

The global ophthalmology therapeutics market is expected to post a CAGR of close to 6% during the period 2019-2023, according to the latest market research report by Technavio.

Technavio has announced the release of their research report on the global splenomegaly therapeutics market for the forecast period 2019-2023.

The global sinus dilation devices market is expected to post a CAGR of about 9% during the period 2019-2023, according to the latest market research report by Technavio.

The global heart valve repair and replacement devices market is expected to post a CAGR of close to 16% during the period 2019-2023, according to the latest market research report by Technavio.

The global gene therapy for CNS disorders market is expected to post a CAGR of close to 27% during the period 2019-2023, according to the latest market research report by Technavio.

Rising Pharma Holdings, Inc., f. k. a. Shore Suven Pharma, Inc., announced today that it completed the purchase of the assets of Rising Pharmaceuticals and Rising’s subsidiaries on a cash-free and debt-free basis.

Evolent Health, Inc. (NYSE: EVH) (“Evolent”), a company providing an integrated value-based care platform to the nation’s leading provider and payer organizations, will release its first quarter 2019 operating results on Tuesday, May 7, 2019 after market close, with a conference call to follow at 5:00 p.m. Eastern Time.

Published in Nature Medicine* today, results of WINTHER, the first study pioneered by the WIN Consortium** - - Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone.